Table 2 Immunohistochemical molecular marker expression in patients with mSBA and comparison of the expression between the primary tumour location in duodenum/jejunum and the ileum
Primary tumour location | Total | Duodenum/ Jejunum | Ileum | P value |
|---|---|---|---|---|
All, n | 74 | 65 (38/ 27) | 9 | Â |
Specimens (biopsy), n (%) | 35 (47.3) | 34 (52.3) | 1 (11.1) | 0.030 |
VEGF-A (high), n (%) | 42 (56.8) | 39 (60.0) | 3 (33.3) | 0.162 |
CD10 (positive), n (%) | 55 (74.3) | 48 (73.9) | 7 (77.8) | 1.000 |
MUC2 (positive), n (%) | 59 (79.7) | 50 (76.9) | 9 (100.0) | 0.189 |
MUC5AC (positive), n (%) | 45 (60.8) | 43 (66.2) | 2 (22.0) | 0.023 |
MUC6 (positive), n (%) | 29 (39.2) | 29 (44.6) | 0 (0.0) | 0.009 |
Mucinous immunophenotype | ||||
 Intestinal type, n (%) | 23 (31.1) | 16 (24.6) | 7 (77.8) | 0.003 |
 Gastrointestinal type, n (%) | 45 (60.8) | 43 (66.2) | 2 (22.2) | 0.023 |
 Gastric type, n (%) | 5 (6.8) | 5 (7.7) | 0 (0.0) | 1.000 |
 Null type, n (%) | 1 (1.4) | 1 (1.5) | 0 (0.0) | 1.000 |
TP53 (high), n (%) | 32 (43.2) | 27 (41.5) | 5 (55.6) | 0.487 |
Ki67 (high), n (%) | 56 (75.7) | 50 (76.9) | 6 (66.7) | 0.679 |
β-catenin (positive), n (%) | 9 (12.2) | 8 (12.3) | 1 (11.1) | 1.000 |
MMRD, n (%) | 4 (5.4) | 3 (4.6) | 1 (11.1) | 0.411 |